Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-23-007010
Filing Date
2023-03-03
Accepted
2023-03-03 17:00:33
Documents
1
Period of Report
2023-03-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4088
  Complete submission text file 0000899243-23-007010.txt   5465
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address
Werner Milton H. (Reporting) CIK: 0001827621 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39676 | Film No.: 23705374